Molecular determinants of resistance to CDK4/6 inhibition in ER plus breast cancer

被引：0
|
作者：
Luo, F. [1 ,2 ]
Cowley, G. [3 ]
Garraway, L. [1 ,2 ]
机构：
[1] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[2] Broad Inst, Med Oncol, Boston, MA USA
[3] Janssen Pharmaceut Co, Johnson & Johnson, Funct Genom, Discovery Sci, Perkasie, PA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2016年 / 69卷
关键词：
D O I：
10.1016/S0959-8049(16)32819-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
224
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [1] Mechanisms of resistance to CDK4/6 inhibition in ER plus breast cancer
    Lee, N. V.
    Eisele, K. J.
    Chionis, J.
    Yuan, J.
    Zhu, Z.
    Liu, C.
    Li, D.
    Olson, P. A.
    Fantin, V.
    Arndt, K. T.
    Shields, D. J.
    VanArsdale, T. L.
    CANCER RESEARCH, 2016, 76
  • [2] Bromodomain inhibition reduces CDK6 expression and reverses CDK4/6 inhibitor resistance in ER plus breast cancer
    Liu, Renyan
    Pantelidou, Constantia
    Jadhav, Heta
    Shapiro, Geoffrey
    CANCER RESEARCH, 2022, 82 (12)
  • [3] RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER plus breast cancer
    Kindt, Charlotte K.
    Ehmsen, Sidse
    Traynor, Sofie
    Policastro, Benedetta
    Nissen, Nikoline
    Jakobsen, Mie K.
    Hundebol, Monique F.
    Johansen, Lene E.
    Bak, Martin
    Arbajian, Elsa
    Staaf, Johan
    Ditzel, Henrik J.
    Alves, Carla L.
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [4] Unveiling mechanisms of CDK4/6 inhibitor resistance in ER plus breast cancer models with acquired resistance
    Li, Bin
    Liu, Gaoxiang
    Ni, Ting
    Shi, Wenting
    Gu, Qingyang
    CANCER RESEARCH, 2024, 84 (06)
  • [5] Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER plus breast cancer
    Formisano, Luigi
    Lu, Yao
    Servetto, Alberto
    Hanker, Ariella B.
    Jansen, Valerie M.
    Bauer, Joshua A.
    Sudhan, Dhivya R.
    Guerrero-Zotano, Angel L.
    Croessmann, Sarah
    Guo, Yan
    Ericsson, Paula Gonzalez
    Lee, Kyung-Min
    Nixon, Mellissa J.
    Schwarz, Luis J.
    Sanders, Melinda E.
    Dugger, Teresa C.
    Cruz, Marcelo Rocha
    Behdad, Amir
    Cristofanilli, Massimo
    Bardia, Aditya
    O'Shaughnessy, Joyce
    Nagy, Rebecca J.
    Lanman, Richard B.
    Solovieff, Nadia
    He, Wei
    Miller, Michelle
    Su, Fei
    Shyr, Yu
    Mayer, Ingrid A.
    Balko, Justin M.
    Arteaga, Carlos L.
    NATURE COMMUNICATIONS, 2019, 10 (1)
  • [6] CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER plus breast cancer
    Zheng, Ze-Yi
    Chen, Anran
    Jaehnig, Eric
    Anurag, Meenakshi
    Lei, Jonathan
    Wang, Chenwei
    Feng, Long
    Singh, Purba
    Kennedy, Hilda
    Cao, Jin
    Yadav, Ghazal
    Tsai, Jill
    Chen, Xi
    Foulds, Charles
    Lim, Bora
    Ellis, Matthew
    Zhang, Bing
    Chang, Eric
    CANCER RESEARCH, 2024, 84 (09)
  • [7] Metabolic reprogramming of ER plus breast cancer cells in response and resistance to the CDK4/6 inhibitor palbociclib
    Lorito, Nicla
    Bacci, Marina
    Smiriglia, Alfredo
    Parri, Matteo
    Malorni, Luca
    Di Leo, Angelo
    Chiarugi, Paola
    Morandi, Andrea
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 180 (02) : 529 - 530
  • [8] ESR1 mutations drive resistance to CDK4/6 inhibitors in ER plus Breast Cancer
    Chica-Parrado, M. Rosario
    Lin, Chang-Ching
    Jaeger, Ellen
    Harris, Michelle
    Guo, Lei
    Bikorimana, Emmanuel
    Napolitano, Fabiana
    Chao, Calvin
    Hanker, Ariella
    Arteaga, Carlos
    CANCER RESEARCH, 2024, 84 (09)
  • [9] The role of FGF/FGFR axis in resistance to SERDs and CDK4/6 inhibitors in ER plus breast cancer
    Mao, Pingping
    Kusiel, Justin
    Cohen, Ofir
    Wagle, Nikhil
    CANCER RESEARCH, 2018, 78 (04)
  • [10] PALBOCICLIB: CDK4/6 INHIBITION IN THE TREATMENT OF ER-POSITIVE BREAST CANCER
    Owsley, J.
    Jimeno, A.
    Diamond, J. R.
    DRUGS OF TODAY, 2016, 52 (02) : 119 - 129
12345